Non-alcoholic steatohepatitis (NASH) is rapidly emerging as a leading cause of chronic liver disease, presenting significant challenge due to the limited treatment options available. This EASL Studio JHEP Live aims to explore novel and promising treatments currently being evaluated for the treatment of NASH. In particular: ARO-HSD, an HSD17β13 inhibitor.PXL065 under evaluation in the DESTINY-1 trial.The investigation of an FXR agonist in fibrotic NASH as part of the LIVIFY trial.Faculty Prof. Vlad Ratziu (Moderator)Prof. Stephen Harrison (Faculty)Dr Rohit Loomba (Faculty)Dr Loey Lung-Yi Mak (Faculty)Related articles A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitisEvaluation of PXL065 – deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1)Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASHAll EASL Studio Podcasts are available on EASL Campus.